Reclassification of redeemable noncontrolling interest to permanent equity Reclassification of redeemable noncontrolling interest to permanent equity Reclassifications of Temporary to Permanent Equity Stock conversion ratio Redeemable Non Controlling Interest Exchange Agreement Stock Conversion Ratio Redeemable non controlling interest exchange agreement stock conversion ratio. vTv Therapeutics LLC V Tv L L C [Member] vTv LLC. Adjustments to reconcile net loss before noncontrolling interest to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Statistical Measurement Statistical Measurement [Domain] Related-Party Transactions Related Party Transactions Disclosure [Text Block] Cover [Abstract] Cover [Abstract] Net increase (decrease) in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Current portion of notes payable Notes Payable, Current Schedule of Maturities of Lease Liabilities for Operating Leases Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Proceeds from collection of notes receivable Proceeds from Collection of Notes Receivable Trading Symbol Trading Symbol All Trading Arrangements All Trading Arrangements [Member] Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Non-NEOs Non-NEOs [Member] Reconciliation of the Numerator and Denominator Used in the Calculation of Basic and Diluted Net Loss per Share of Class A Common Stock Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Non-qualified stock option awards vesting period Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Collaborative arrangement, contingent consideration Collaborative Arrangement, Contingent Consideration Transferred, Aggregate Share Value Collaborative Arrangement, Contingent Consideration Transferred, Aggregate Share Value (Decrease)/Increase in vTv Therapeutics Inc. stockholders' equity (deficit) for sale of vTv Units as a result of common stock issuances Consolidation Changes Wholly Owned Subsidiary Parent Ownership Interest Changes Purchase Of Interest By Parent Consolidation changes wholly owned subsidiary parent ownership interest changes purchase of interest by parent. Class A Common Stock Common Class A [Member] Pay vs Performance Disclosure [Line Items] Discount rate Notes Receivable, Discount Rate Notes Receivable, Discount Rate Redeemable noncontrolling interest Beginning balance Ending balance Redeemable Noncontrolling Interest, Equity, Carrying Amount Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Accounts receivable Increase (Decrease) in Accounts Receivable Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Receivables, fair value disclosure Receivables, Fair Value Disclosure Fair Value of Financial Instruments Fair Value Disclosures [Text Block] MacAndrews & Forbes Incorporated Mac Andrews And Forbes Incorporated [Member] MacAndrews and Forbes Incorporated. Award Timing Disclosures [Line Items] Other Performance Measure, Amount Other Performance Measure, Amount Type 2 Diabetes Type Two Diabetes [Member] Type 2 diabetes. Leases Lessee, Operating Leases [Text Block] Common stock, shares outstanding (in shares) Beginning balance, shares (in shares) Ending balance, shares (in shares) Common Stock, Shares, Outstanding Operating lease cost Operating Lease, Cost Class of Warrant or Right [Axis] Class of Warrant or Right [Axis] Lessee, operating lease, termination period Lessee, Operating Lease, Termination Period Lessee, Operating Lease, Termination Period Operating lease liabilities, net of current portion Operating Lease, Liability, Noncurrent Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] Fair Value Measurement Inputs and Valuation Techniques [Line Items] Organization Consolidation And Presentation Of Financial Statements [Line Items] Organization Consolidation And Presentation Of Financial Statements [Line Items] Organization consolidation and presentation of financial statements. Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Warrants, term Expected life of options in years Warrants and Rights Outstanding, Term Current portion of contract liabilities Contract with Customer, Liability, Current Sale of stock, price per share (in usd per share) Sale of Stock, Price Per Share Entity Tax Identification Number Entity Tax Identification Number Leases [Abstract] Leases [Abstract] Reclass Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Reclass Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Reclass Antidilutive Securities, Name Antidilutive Securities, Name [Domain] Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Sale of stock, consideration received on transaction Sale of Stock, Consideration Received on Transaction Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Redeemable noncontrolling interest, equity, fair value Redeemable Noncontrolling Interest, Equity, Fair Value Equity Components Equity Components [Axis] Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Award Timing Method Award Timing Method [Text Block] Research and Development Research and Development Expense, Policy [Policy Text Block] Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Options vested and expected to vest (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price Noncontrolling Interest [Line Items] Noncontrolling Interest [Line Items] Measurement Frequency Measurement Frequency [Axis] Entity Common Stock, Shares Outstanding (in shares) Entity Common Stock, Shares Outstanding Proceeds from G42 Promissory Note early redemption related to sale of Class A common stock to collaboration partner Proceeds From Sale Of Common Stock Proceeds From Sale Of Common Stock Insider Trading Policies and Procedures [Line Items] Use of Estimates Use of Estimates, Policy [Policy Text Block] Adjustment to Compensation, Amount Adjustment to Compensation Amount Additional paid-in capital Additional Paid in Capital, Common Stock Reclassification of noncontrolling interest to additional paid-in capital Noncontrolling Interest, Reclassification to Additional Paid-in-Capital Noncontrolling Interest, Reclassification to Additional Paid-in-Capital Compensation Amount Outstanding Recovery Compensation Amount Non-cash activities: Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member] Entity Small Business Entity Small Business Company Selected Measure Amount Company Selected Measure Amount Tabular List, Table Tabular List [Table Text Block] Novo License Agreement Novo License Agreement [Member] Novo license agreement. Significant Unobservable Inputs (Level 3) Fair Value, Inputs, Level 3 [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Weighted Average Weighted Average [Member] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Table] Fair Value Measurement Inputs and Valuation Techniques [Table] Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member] Number of securities called by warrants or rights (in shares) Class of Warrant or Right, Number of Securities Called by Warrants or Rights Potentially dilutive securities not included in calculation of dilutive net loss per share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Redeemable Noncontrolling Interest Redeemable Noncontrolling Interests [Member] Redeemable noncontrolling interests. Expected dividend yield Measurement Input, Expected Dividend Rate [Member] Summary of Net Income Attributable to Vtv Therapeutics Inc Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Table Text Block] Total cash and cash equivalents, beginning of period Total cash and cash equivalents, end of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Current assets: Assets, Current [Abstract] Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Product and Service Product and Service [Domain] Stock Option Common stock options granted under the Plan Share-Based Payment Arrangement, Option [Member] Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Depreciation expense Depreciation 2025 Lessee, Operating Lease, Liability, to be Paid, Year One Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table] Antidilutive Security, Excluded EPS Calculation [Table] Common stock warrants Warrant liability, related party Warrant [Member] Security Exchange Name Security Exchange Name Award Type Award Type [Axis] Revenue recognized from change in estimated transaction prices Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Change in Estimate of Transaction Price Related Party Transaction [Domain] Related Party Transaction [Domain] Issuance of Class A Common Stock under ATM offering (in shares) Issuance Of Class A Common Stock Under A T M Offering Shares Issuance Of Class A Common Stock Under A T M Offering Shares Property and equipment, net Property, Plant and Equipment, Net Total liabilities Liabilities Noncontrolling interest Equity, Attributable to Noncontrolling Interest Options exercisable (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Sale of stock, consideration received on transaction, gross Sale of Stock, Consideration Received on Transaction, Gross Sale of Stock, Consideration Received on Transaction, Gross Common stock par value (in usd per share) Common Stock, Par or Stated Value Per Share Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Research and development Research and Development Expense Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Expiration Date Trading Arrangement Expiration Date Share held by related party (in shares) Investment Owned, Balance, Shares Current portion of operating lease liabilities Operating Lease, Liability, Current Total Shareholder Return Amount Total Shareholder Return Amount Entity Entity [Domain] Equity Awards Adjustments, Footnote Equity Awards Adjustments, Footnote [Text Block] Concentration risk percentage Concentration Risk, Percentage Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Research and development Research and Development Expense [Member] Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Common stock, shares authorized (in shares) Common Stock, Shares Authorized Weighted-average number of vTv Therapeutics Inc. Class A Common Stock, diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Commitments And Contingencies [Line Items] Commitments And Contingencies [Line Items] Commitments and Contingencies. CinRx Warrants CinRx Warrants [Member] CinRx Warrants MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Percent of public float Sale of Stock, Maximum Securities To Be Sold, Percent Of Public Float Sale of Stock, Maximum Securities To Be Sold, Percent Of Public Float Aggregate offering price Sale Of Stock, Aggregate Offering Price Aggregate offering price. Total stockholders’ equity (deficit) attributable to vTv Therapeutics Inc. Equity, Attributable to Parent Net loss attributable to redeemable noncontrolling interest Temporary Equity, Net Income Collaboration Agreements Collaborative Arrangement Disclosure [Text Block] Related Party Related Party [Member] Lessee, operating lease, renewal term Lessee, Operating Lease, Renewal Term Amount of cash savings percentage Percentage Of Amount Of Cash Savings Percentage of amount of cash savings. Collaborate arrangement, contingent consideration transferred, cash Collaborate Arrangement, Contingent Consideration Transferred, Cash Collaborate Arrangement, Contingent Consideration Transferred, Cash Type 1 Diabetes Type One Diabetes [Member] Type 1 diabetes. Concentration Risk Type Concentration Risk Type [Domain] Fair Value, Measurements, Recurring Fair Value, Recurring [Member] Accounts receivable Accounts Receivable, after Allowance for Credit Loss, Current Stock Conversion Description Stock Conversion Description [Axis] Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] G42 Investments G42 Investments [Member] G42 Investments Sale of Stock [Domain] Sale of Stock [Domain] Other liabilities Increase (Decrease) in Other Operating Liabilities Pension Adjustments Prior Service Cost Pension Adjustments Prior Service Cost [Member] Document Fiscal Period Focus Document Fiscal Period Focus Income Taxes [Table] Income Taxes [Table] Income taxes. All Executive Categories All Executive Categories [Member] Schedule Of Earnings Per Share [Line Items] Schedule Of Earnings Per Share [Line Items] Schedule Of Earnings Per Share [Line Items] Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Assets Assets [Abstract] Document Type Document Type Pension Benefits Adjustments, Footnote Pension Benefits Adjustments, Footnote [Text Block] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Nonrelated Party Nonrelated Party [Member] Options exercisable, weighted average remaining contractual term Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Total vTv Therapeutics Inc Stockholders’ Equity (Deficit) Parent [Member] Research and Development Arrangement, Contract to Perform for Others, Type Research and Development Arrangement, Contract to Perform for Others, Type [Domain] Maximum Maximum [Member] Parent Company Parent Company [Member] Summary Of Significant Accounting Policies [Table] Summary Of Significant Accounting Policies [Table] Summary Of Significant Accounting Policies [Table] Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Antidilutive Securities Antidilutive Securities [Axis] Accounting Policies [Abstract] Accounting Policies [Abstract] Current Fiscal Year End Date Current Fiscal Year End Date Statistical Measurement Statistical Measurement [Axis] PEO Name PEO Name Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Loss before income taxes and noncontrolling interest Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Expense reduction Share-Based Payment Arrangement, Expense Reduction, Amount Share-Based Payment Arrangement, Expense Reduction, Amount Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Award Type Award Type [Domain] Name Outstanding Recovery, Individual Name Schedule of Potentially Dilutive Securities not Included in Calculation of Diluted Net Loss per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Non-PEO NEO Non-PEO NEO [Member] Additional Paid-in Capital Additional Paid-in Capital [Member] Issuance of Class A Common Stock under ATM offering Issuance of Class A Common Stock under ATM offering Issuance of Class A Common Stock under ATM offering Award Timing Predetermined Award Timing Predetermined [Flag] Collaborative Arrangements Collaborative Arrangement [Member] Class Of Stock [Line Items] Class of Stock [Line Items] Proceeds from sale of Class A common stock and pre-funded warrants, net of offering costs Proceeds from Issuance of Preferred Stock, Preference Stock, and Warrants Recently Issued Accounting Pronouncements Not Yet Adopted New Accounting Pronouncements, Policy [Policy Text Block] Net loss per share of vTv Therapeutics Inc. Class A Common Stock, diluted (in usd per share) Earnings Per Share, Diluted Class of Stock Class of Stock [Axis] Counterparty Name [Domain] Counterparty Name [Domain] Revenue Recognition Revenue from Contract with Customer [Policy Text Block] Name Measure Name Entity Interactive Data Current Entity Interactive Data Current Organization Consolidation And Presentation Of Financial Statements [Table] Organization Consolidation And Presentation Of Financial Statements [Table] Organization Consolidation And Presentation Of Financial Statements [Table] Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Number of days used to determine exchange value based on weighted average price of Class A common stock Period Used To Determine Exchange Value Based On Weighted Average Price Of Class Common Stock Period used to determine exchange value based on weighted average price of Class A common stock. Newsoara Biopharma Co Ltd Newsoara Biopharma Co Ltd [Member] Newsoara Biopharma Co Ltd. Options vested and expected to vest, weighted average remaining contractual term Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term Private Placement Pre-Funded Warrants Private Placement Pre-Funded Warrants [Member] Private Placement Pre-Funded Warrants Change in fair value of warrants Fair Value Adjustment of Warrants Less: imputed interest Operating Leases Imputed Interest Operating leases imputed interest. Customer [Axis] Customer [Axis] Summarizes the Conclusions Reached Regarding Fair Value Measurements Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] JDRF J D R F International [Member] JDRF international. Share-based compensation expense Share-Based Payment Arrangement, Noncash Expense License fee received, term License Fee Received, Term License Fee Received, Term Net loss before noncontrolling interest Net loss before noncontrolling interest Net loss Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net Change in fair value included in earnings Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Gain (Loss) Included in Earnings Income tax provision Income Tax Expense (Benefit) Purchases / Issuance Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases Current deposits Deposits Assets, Current Net loss attributable to common shareholders of vTv Therapeutics Inc., diluted Net Income (Loss) Available to Common Stockholders, Diluted Weighted average period to recognize unrecognized share-based compensation cost Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Revenue Revenue from Contract with Customer, Excluding Assessed Tax License fee price increase License Fee Price Increase License Fee Price Increase Concentration Risk Benchmark Concentration Risk Benchmark [Domain] Operating loss Operating Income (Loss) Proceeds from issuance of private placement Proceeds from Issuance of Private Placement Total liabilities, redeemable noncontrolling interest and stockholders’ equity (deficit) Liabilities and Equity M&F TTP Holdings LLC M F T T P Holdings L L C [Member] M&F TTP Holdings LLC. Subsequent Events Subsequent Events [Text Block] Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] All Adjustments to Compensation All Adjustments to Compensation [Member] Fair Value Hierarchy and NAV Fair Value Hierarchy and NAV [Axis] Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Minority Interest [Table] Noncontrolling Interest [Table] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Legal Entity Legal Entity [Axis] Interest income Investment Income, Interest Potential milestone payment Potential Milestone Payment Potential milestone payment. Proceeds from debt issuance Proceeds from Notes Payable Underlying Security Market Price Change Underlying Security Market Price Change, Percent Measurement Input Type Measurement Input Type [Axis] Individual: Individual [Axis] Related Party Transaction [Axis] Related Party Transaction [Axis] Forfeited (in usd per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Product and Service Product and Service [Axis] Entity Address, State or Province Entity Address, State or Province Change in redemption value of noncontrolling interest Noncontrolling Interest, Change in Redemption Value Statement [Line Items] Statement [Line Items] Measurement Input Type Measurement Input Type [Domain] Fair Value Of Assets And Liabilities Measured On Recurring Basis [Table] Fair Value Of Assets And Liabilities Measured On Recurring Basis [Table] Fair value of assets and liabilities measured on recurring basis table. Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Operating expenses: Operating Expenses [Abstract] Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Financial Instruments Financial Instruments [Domain] Liabilities, Redeemable Noncontrolling Interest and Stockholders’ Equity (Deficit) Liabilities and Equity [Abstract] Beginning Balance Ending Balance Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Potential development and regulatory milestone payments Potential Development And Regulatory Milestone Payments Receivable Potential development and regulatory milestone payments receivable. Minimum Minimum [Member] Restatement Determination Date Restatement Determination Date Adoption Date Trading Arrangement Adoption Date Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Inputs utilized in the valuation of warrants Warrants and Rights Outstanding, Measurement Input Related Party Transactions [Abstract] Related Party Transactions [Abstract] Contract liabilities, net of current portion Contract with Customer, Liability, Noncurrent Awards outstanding, Beginning balance (in usd per share) Awards outstanding, Ending balance (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Operating lease right-of-use assets Operating Lease, Right-of-Use Asset Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Awards outstanding, Beginning balance (in shares) Awards outstanding, Ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Discount on note receivable Collaborative Arrangement, Note Receivable, Discount Paid Collaborative Arrangement, Note Receivable, Discount Paid Income Taxes [Line Items] Income Taxes [Line Items] Income taxes. Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member] Exercise Price Award Exercise Price Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items] Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items] Fair value of assets and liabilities measured on recurring basis. Net Loss per Share Earnings Per Share [Text Block] Arrangement Duration Trading Arrangement Duration Stockholders’ equity (deficit): Equity, Attributable to Parent [Abstract] Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Warrant liability, related party Warranty Liability Warranty Liability Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Percent of securities called by warrants Class of Warrant or Right, Percent of Securities Called by Warrants or Rights Class of Warrant or Right, Percent of Securities Called by Warrants or Rights All Individuals All Individuals [Member] PEO PEO [Member] Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Name Trading Arrangement, Individual Name Other income (expense), net Other Nonoperating Income (Expense) Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] CinRx Investment CinRx Investment [Member] CinRx Investment Change from net loss attributable to vTv Therapeutics Inc. common shareholders and transfers to noncontrolling interest Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Change Due to Net Income Attributable to Parent and Effects of Changes, Net Modified common stock (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Modified Common Stock Share-Based Compensation Arrangement by Share-Based Payment Award, Modified Common Stock Options vested and expected to vest (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number Developmental and Regulatory Milestone Payment Developmental And Regulatory Milestone Payment [Member] Developmental and regulatory milestone payment. Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Other Commitments Other Commitments [Domain] Expected volatility Measurement Input, Price Volatility [Member] Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member] Related Party Related and Nonrelated Parties [Domain] Royalties receivable, period Collaborative Arrangement, Royalties Receivable, Period Collaborative Arrangement, Royalties Receivable, Period Accounts payable and accrued expenses Accounts Payable and Accrued Liabilities, Current Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Local Phone Number Local Phone Number Thereafter Lessee, Operating Lease, Liability, to be Paid, After Year Four Lessee, Operating Lease, Liability, to be Paid, After Year Four Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Total operating expenses Operating Expenses Change in fair value of investments Unrealized Gain (Loss) on Investments Entity public float, threshold Entity Public Float, Threshold Entity Public Float, Threshold Other assets Increase (Decrease) in Other Operating Assets Changes in assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] PEO Total Compensation Amount PEO Total Compensation Amount Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Other Indication Other Indication [Member] Other indication. Capital stock, shares authorized (in shares) Common Stock And Preferred Stock Shares Authorized Common stock and preferred stock shares authorized. Income Statement Location Statement of Income Location, Balance [Axis] Cash and Cash Equivalents Cash and Cash Equivalents, Policy [Policy Text Block] Percentage of non-voting economic interest of vTv Therapeutics Inc in vTv LLC Percentage Of Non Voting Economic Interest By Parent Percentage of non voting economic interest by parent. Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Common Stock Common Stock [Member] Measure: Measure [Axis] Maximum funding percentage of research and development milestones Maximum Funding Percentage Of Research And Development Milestones Maximum funding percentage of research and development milestones. Shares authorized (in shares) Preferred Stock, Shares Authorized Stock split conversion ratio Stockholders' Equity Note, Stock Split, Conversion Ratio Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount G2 Investments Purchase Agreement And Cogna Collaborative And License Agreement G2 Investments Purchase Agreement And Cogna Collaborative And License Agreement [Member] G2 Investments Purchase Agreement And Cogna Collaborative And License Agreement Issuance of Class A common stock and prefunded warrants, net offering costs (in shares) Stock Issued During Period, Shares, New Issues Entity Emerging Growth Company Entity Emerging Growth Company Liabilities: Liabilities, Fair Value Disclosure Entity Central Index Key Entity Central Index Key General and administrative General and Administrative Expense [Member] Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Stockholders' Equity (Deficit) Equity [Text Block] Accounts payable and accrued expenses Increase (Decrease) in Accounts Payable and Accrued Liabilities Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Preferred stock, par or stated value per share (in usd per share) Preferred Stock, Par or Stated Value Per Share Equity Component Equity Component [Domain] Financial Instrument Financial Instrument [Axis] Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Share-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Risk-free interest rate Measurement Input, Risk Free Interest Rate [Member] Exchange of Redeemable Non controlling Interest To Class A Common Stock Exchange Of Redeemable Non Controlling Interest To Class A Common Stock [Member] Exchange of redeemable non controlling interest to class A common stock. Entity Shell Company Entity Shell Company Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Class B Common Stock Common Class B [Member] Title Trading Arrangement, Individual Title Consolidated Entities [Axis] Consolidated Entities [Axis] Statement [Table] Statement [Table] Schedule Of Earnings Per Share [Table] Schedule Of Earnings Per Share [Table] Schedule Of Earnings Per Share [Table] Measurement Frequency Measurement Frequency [Domain] Counterparty Name [Axis] Counterparty Name [Axis] Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Sales-based Milestones Payment Sales Based Milestones Payment [Member] Sales-based milestones payment. City Area Code City Area Code Current liabilities: Liabilities, Current [Abstract] Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Quoted Prices in Active Markets for Identical Assets (Level 1) Fair Value, Inputs, Level 1 [Member] License fee received License Fee Received License Fee Received Concentration Risk Benchmark Concentration Risk Benchmark [Axis] Total current assets Assets, Current Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Sale of stock, consideration, receivables, payment term Sale Of Stock, Consideration, Receivable, Term Sale Of Stock, Consideration, Receivable, Term Options exercisable (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Summary Of Significant Accounting Policies [Line Items] Summary Of Significant Accounting Policies [Line Items] Summary of significant accounting policies. Document Information [Line Items] Document Information [Line Items] Fair Value Measurement Inputs and Valuation Techniques Fair Value Measurement Inputs and Valuation Techniques [Table Text Block] Weighted average grant date fair value of options granted (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Other Commitments Other Commitments [Axis] Income Taxes Income Tax Disclosure [Text Block] 2028 Lessee, Operating Lease, Liability, to be Paid, Year Four Earnings Per Share [Abstract] Earnings Per Share [Abstract] Numerator: Net Income (Loss) Attributable to Parent [Abstract] Equity [Abstract] Equity [Abstract] Accumulated deficit Retained earnings (accumulated deficit) Retained Earnings (Accumulated Deficit) Percentage of non-voting economic interest of vTv Therapeutics Holdings LLC in vTv LLC Noncontrolling interest ownership percentage Percentage Of Non Voting Economic Interest Percentage of non voting economic interest. Class of Stock Class of Stock [Domain] Research and Development Arrangement, Contract to Perform for Others, Type Research and Development Arrangement, Contract to Perform for Others, Type [Axis] Related Party Transaction [Line Items] Related Party Transaction [Line Items] Net loss attributable to vTv Therapeutics Inc. Net Income (Loss), Including Portion Attributable to Nonredeemable Noncontrolling Interest General and administrative General and Administrative Expense Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Equity Awards Adjustments Equity Awards Adjustments [Member] Weighted average incremental borrowing rate Operating Lease, Weighted Average Discount Rate, Percent Unaudited Interim Financial Information Unaudited Interim Financial Information Policy [Policy Text Block] Unaudited interim financial information policy. Present value of lease liabilities Operating Lease, Liability Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Underlying Securities Award Underlying Securities Amount Conversion of Stock, Name Conversion of Stock, Name [Domain] Amendment Flag Amendment Flag Entity Registrant Name Entity Registrant Name Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward] Increase (Decrease) in Temporary Equity [Roll Forward] Net loss attributable to noncontrolling interest Net Income (Loss) Attributable to Nonredeemable Noncontrolling Interest Fair Value as of Grant Date Award Grant Date Fair Value Customer Customer Concentration Risk [Member] Subsequent Events [Abstract] Subsequent Events [Abstract] Significant Other Observable Inputs (Level 2) Fair Value, Inputs, Level 2 [Member] Shares sold (in shares) Sale of Stock, Number of Shares Issued in Transaction Fair Value Hierarchy and NAV Fair Value Hierarchy and NAV [Domain] Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Issuance of Class A common stock and pre-funded warrants, net offering costs Stock Issued During Period, Value, New Issues Entity Address, Postal Zip Code Entity Address, Postal Zip Code Collaborative Arrangement and Arrangement Other than Collaborative Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Summary of Compensation Expense Related to Grants of Stock Options Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Restatement Determination Date: Restatement Determination Date [Axis] Letter Agreement Warrants Letter Agreement Warrants [Member] Letter agreement warrants. Collaborative Arrangement and Arrangement Other than Collaborative Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Title of 12(b) Security Title of 12(b) Security Concentration Risk Type Concentration Risk Type [Axis] Common stock value Common Stock, Value, Issued Increase in shares authorized (in shares) Increase In Common Stock Shares Authorized Increase in common stock shares authorized. Share-based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Cogna Cogna [Member] Cogna Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member] Loss from G42 promissory note early redemption Gain (loss) on extinguishment of debt Gain (Loss) on Extinguishment of Debt TD Cowen Sales Agreement TD Cowen Sales Agreement [Member] TD Cowen Sales Agreement Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member] Number of Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Noncontrolling Interest Noncontrolling Interest Disclosure [Text Block] Net loss per share of vTv Therapeutics Inc. Class A Common Stock, basic (in usd per share) Earnings Per Share, Basic Proceeds from sale of Class A common stock, net of offering costs Proceeds from Issuance of Common Stock Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Non-qualified stock option awards expiration term Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period One Customer One Customer [Member] One Customer Commitments And Contingencies [Table] Commitments And Contingencies [Table] Commitments And Contingencies [Table] Aggregate Pension Adjustments Service Cost Aggregate Pension Adjustments Service Cost [Member] Net loss attributable to vTv Therapeutics Inc. common shareholders Net loss attributable to common shareholders of vTv Therapeutics Inc., basic Net Income (Loss) Available to Common Stockholders, Basic Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Schedule Of Stock By Class [Table] Stock, Class of Stock [Table] Total current liabilities Liabilities, Current Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member] Denominator: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Unrecognized compensation cost related to non-vested share-based compensation arrangements Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Total assets Assets Concentration of Credit Risk Concentration Risk, Credit Risk, Policy [Policy Text Block] Repayment of notes payable Repayments of Notes Payable Change in redemption value of noncontrolling interest Change In Redemption Value Of Noncontrolling Interest Change In Redemption Value Of Noncontrolling Interest Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Commitments and contingencies Commitments and Contingencies Accelerated vesting (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Accelerated Vesting, Number License And Technology Transfer Services License And Technology Transfer Services [Member] License and technology transfer services. Termination Date Trading Arrangement Termination Date Class of Warrant or Right [Domain] Class of Warrant or Right [Domain] Description of Business and Basis of Presentation Business Description and Basis of Presentation [Text Block] Schedule Of Related Party Transactions By Related Party [Table] Related Party Transaction [Table] Exercise price of warrants or rights (in usd per share) Class of Warrant or Right, Exercise Price of Warrants or Rights 2026 Lessee, Operating Lease, Liability, to be Paid, Year Two Share-Based Compensation Share-Based Payment Arrangement [Text Block] Sales / Repurchases Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Sales Entity Address, City or Town Entity Address, City or Town Summary of Stock Award Activity for the Period Share-Based Payment Arrangement, Option, Activity [Table Text Block] Noncontrolling Interest [Abstract] Noncontrolling Interest [Abstract] Total share-based compensation expense Share-Based Payment Arrangement, Expense Collaboration revenue recognized Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer Net loss attributable to vTv Therapeutics Inc. Net loss attributable to vTv Therapeutics Inc. Net Income (Loss) Attributable to Parent Trading Arrangement: Trading Arrangement [Axis] Granted (in usd per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Equity Awards Adjustments, Excluding Value Reported in Compensation Table Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member] Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member] Entity File Number Entity File Number Consolidated Entities [Domain] Consolidated Entities [Domain] Document Fiscal Year Focus Document Fiscal Year Focus Noncontrolling Interest Noncontrolling Interest [Member] Income Statement [Abstract] Income Statement [Abstract] Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Name Forgone Recovery, Individual Name 2024 (remaining three months) Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Remaining operating lease term Operating Lease, Weighted Average Remaining Lease Term Document Period End Date Document Period End Date Sale of Stock [Axis] Sale of Stock [Axis] Investments Investment, Policy [Policy Text Block] Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Impairment of investments in Anteris Bio, Inc Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount Total lease payments Lessee, Operating Lease, Liability, to be Paid Insider Trading Arrangements [Line Items] Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount 2027 Lessee, Operating Lease, Liability, to be Paid, Year Three PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Non-cash interest income Interest Income, Operating Private placement pre-funded warrants, shares (in shares) Common Stock, Par or Stated Value of Private Placement Pre-Funded Warrants, Shares Common Stock, Par or Stated Value of Private Placement Pre-Funded Warrants, Shares Contract with customer, liability, revenue recognized Contract with Customer, Liability, Revenue Recognized Warrants, fair value Warrants and Rights Outstanding Adjustment to Compensation: Adjustment to Compensation [Axis] Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Less: net loss attributable to noncontrolling interest Net Income (Loss) Attributable to Noncontrolling Interest Accounts and financing receivable, after allowance for credit loss Accounts and Financing Receivable, after Allowance for Credit Loss, Current Document Transition Report Document Transition Report Private placement, shares (in shares) Common Stock, Par or Stated Value of Private Placement, Shares Common Stock, Par or Stated Value of Private Placement, Shares Document Quarterly Report Document Quarterly Report Interest expense Interest Expense, Operating Customer [Domain] Customer [Domain] Entity Current Reporting Status Entity Current Reporting Status Accumulated Deficit Retained Earnings [Member] Pension Adjustments Service Cost Pension Adjustments Service Cost [Member] Weighted-average number of vTv Therapeutics Inc. Class A Common Stock, basic (in shares) Weighted Average Number of Shares Outstanding, Basic Related Party Related and Nonrelated Parties [Axis] Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Document Information [Table] Document Information [Table] Total stockholders’ equity (deficit) Beginning balance Ending balance Equity, Including Portion Attributable to Noncontrolling Interest Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Executive Category: Executive Category [Axis] Ownership percentage of majority owner Ownership Percentage Of Majority Owner Ownership percentage of majority owner. Name Awards Close in Time to MNPI Disclosures, Individual Name Revenue Revenue Benchmark [Member] Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Entity Filer Category Entity Filer Category Income Statement Location Statement of Income Location, Balance [Domain] Company Selected Measure Name Company Selected Measure Name Private Placement Private Placement [Member]